AAAAAA
Results:
1-24
|
Results: 24
Authors:
Braun, S
Rosenberg, R
Thorban, S
Harbeck, N
Citation: S. Braun et al., Implications of occult metastatic cells for systemic cancer treatment in patients with breast or gastrointestinal cancer, SEM SURG ON, 20(4), 2001, pp. 334-346
Authors:
Muehlenweg, B
Sperl, S
Magdolen, V
Schmitt, M
Harbeck, N
Citation: B. Muehlenweg et al., Interference with the urokinase plasminogen activator system: a promising therapy concept for solid tumours, EXPERT OP B, 1(4), 2001, pp. 683-691
Authors:
Braun, S
Harbeck, N
Citation: S. Braun et N. Harbeck, Recent advances in technologies for the detection of occult metastatic cells in bone marrow of breast cancer patients, BREAST CA R, 3(5), 2001, pp. 285-288
Authors:
Harbeck, N
Alt, U
Berger, U
Kruger, A
Thomssen, C
Janicke, F
Hofler, H
Kates, RE
Schmitt, M
Citation: N. Harbeck et al., Prognostic impact of proteolytic factors (Urokinase-Type plasminogen activator, plasminogen activator inhibitor 1, and cathepsins B, D, and L) in primary breast cancer reflects effects of adjuvant systemic therapy, CLIN CANC R, 7(9), 2001, pp. 2757-2764
Authors:
Braun, S
Harbeck, N
Pantel, K
Citation: S. Braun et al., Is immunohistochemical analysis an appropriate diagnostic technique for bone marrow micrometastases? - Reply, J CL ONCOL, 19(15), 2001, pp. 3590-3592
Clinical relevance of the plasminogen activator inhibitor type 1 - a multifaceted proteolytic factor
Authors:
Harbeck, N
Kruger, A
Sinz, S
Kates, RE
Thomssen, C
Schmitt, M
Janicke, F
Citation: N. Harbeck et al., Clinical relevance of the plasminogen activator inhibitor type 1 - a multifaceted proteolytic factor, ONKOLOGIE, 24(3), 2001, pp. 238-244
Authors:
Prechtel, D
Harbeck, N
Berger, U
Hofler, H
Werenskiold, AK
Citation: D. Prechtel et al., Clinical relevance of T1-S, an oncogene-inducible, secreted glycoprotein of the immunoglobulin superfamily, in node-negative breast cancer, LAB INV, 81(2), 2001, pp. 159-165
Authors:
Kruger, A
Soeltl, R
Sopov, I
Kopitz, C
Arlt, M
Magdolen, V
Harbeck, N
Gansbacher, B
Schmitt, M
Citation: A. Kruger et al., Hydroxamate-type matrix metalloproteinase inhibitor batimastat promotes liver metastasis, CANCER RES, 61(4), 2001, pp. 1272-1275
Authors:
Schmitt, M
Wilhelm, OG
Reuning, U
Kruger, A
Harbeck, N
Lengyel, E
Graeff, H
Gansbacher, B
Kessler, H
Burgle, M
Sturzebecher, J
Sperl, S
Magdolen, V
Citation: M. Schmitt et al., The urokinase plasminogen activator system as a novel target for tumour therapy, FIBRINOL PR, 14(2-3), 2000, pp. 114-132
Authors:
Werenskiold, AK
Prechtel, D
Harbeck, N
Hofler, H
Citation: Ak. Werenskiold et al., Tumor-associated overexpression of the soluble T1-S receptor in lymph node-negative breast cancer, DIAGN MOL P, 9(1), 2000, pp. 26-34
Authors:
Kotzsch, M
Luther, T
Harbeck, N
Ockert, D
Lutz, V
Noack, E
Grossmann, D
Albrecht, S
Kramer, MD
Lossnitzer, A
Grosser, M
Schmitt, M
Magdolen, V
Citation: M. Kotzsch et al., New ELISA for quantitation of human urokinase receptor (CD87) in cancer, INT J ONCOL, 17(4), 2000, pp. 827-834
Authors:
Schnelzer, A
Prechtel, D
Knaus, U
Dehne, K
Gerhard, M
Graeff, H
Harbeck, N
Schmitt, M
Lengyel, E
Citation: A. Schnelzer et al., Rac1 in human breast cancer: overexpression, mutation analysis, and characterization of a new isoform, Rac1b, ONCOGENE, 19(26), 2000, pp. 3013-3020
Authors:
Prechtl, A
Harbeck, N
Thomssen, C
Meisner, C
Braun, M
Untch, M
Wieland, M
Lisboa, B
Cufer, T
Graeff, H
Selbmann, K
Schmitt, M
Janicke, F
Citation: A. Prechtl et al., Tumor-biological factors uPA and PAI-1 as stratification criteria of a multicenter adjuvant chemotherapy trial in node-negative breast cancer, INT J B MAR, 15(1), 2000, pp. 73-78
Authors:
Harbeck, N
Alt, U
Berger, U
Kates, R
Kruger, A
Thomssen, C
Janicke, F
Graeff, H
Schmitt, M
Citation: N. Harbeck et al., Long-term follow-up confirms prognostic impact of PAI-1 and cathepsin D and L in primary breast cancer, INT J B MAR, 15(1), 2000, pp. 79-83
Authors:
Noack, F
Schmitt, M
Bauer, J
Helmecke, D
Kruger, W
Thorban, S
Sandherr, M
Kuhn, W
Graeff, H
Harbeck, N
Citation: F. Noack et al., A new approach to phenotyping disseminated tumor cells: Methodological advances and clinical implications, INT J B MAR, 15(1), 2000, pp. 100-104
Authors:
Harbeck, N
Kates, R
Ulm, K
Graeff, H
Schmitt, M
Citation: N. Harbeck et al., Neural network analysis of follow-up data in primary breast cancer, INT J B MAR, 15(1), 2000, pp. 116-122
Authors:
Noack, F
Helmecke, D
Rosenberg, R
Thorban, S
Nekarda, H
Fink, U
Lewald, J
Stich, M
Schutze, K
Harbeck, N
Magdolen, V
Graeff, H
Schmitt, M
Citation: F. Noack et al., CD87-positive tumor cells in bone marrow aspirates identified by confocal laser scanning fluorescence microscopy, INT J ONCOL, 15(4), 1999, pp. 617-623
Authors:
Harbeck, N
Ross, JS
Yurdseven, S
Dettmar, P
Polcher, M
Kuhn, W
Ulm, K
Graeff, H
Schmitt, M
Citation: N. Harbeck et al., HER-2/neu gene amplification by fluorescence in situ hybridization allows risk-group assessment in node-negative breast cancer, INT J ONCOL, 14(4), 1999, pp. 663-671
Authors:
Harbeck, N
Thomssen, C
Berger, U
Ulm, K
Kates, RE
Hofler, H
Janicke, F
Graeff, H
Schmitt, M
Citation: N. Harbeck et al., Invasion marker PAI-1 remains a strong prognostic factor after long-term follow-up both for primary breast cancer and following first relapse, BREAST CANC, 54(2), 1999, pp. 147-157
Authors:
Schmitt, M
Kuhn, W
Harbeck, N
Graeff, H
Citation: M. Schmitt et al., Thrombophilic state in breast cancer, SEM THROMB, 25(2), 1999, pp. 157-166
Authors:
DePaola, N
Davies, PF
Pritchard, WF
Florez, L
Harbeck, N
Polacek, DC
Citation: N. Depaola et al., Spatial and temporal regulation of gap junction connexin43 in vascular endothelial cells exposed to controlled disturbed flows in vitro, P NAS US, 96(6), 1999, pp. 3154-3159
Authors:
Schmalfeldt, B
Kuhn, W
Harbeck, N
Spathe, K
Dettmar, P
Berger, U
Schmitt, M
Graeff, H
Citation: B. Schmalfeldt et al., Indicators of proliferation and invasion in ovarian tumors of low malignant potential, GEBURTSH FR, 59(10), 1999, pp. 507-512
Authors:
Harbeck, N
Dettmar, P
Thomssen, C
Berger, U
Ulm, K
Kates, R
Hofler, H
Janicke, F
Graeff, H
Schmitt, M
Citation: N. Harbeck et al., Risk group discrimination in node-negative breast cancer using invasion and proliferation markers: 6-year median follow up, BR J CANC, 80(3-4), 1999, pp. 419-426
Authors:
Kuhn, W
Schmalfeldt, B
Reuning, U
Pache, L
Berger, U
Ulm, K
Harbeck, N
Spathe, K
Dettmar, P
Hofler, H
Janicke, F
Schmitt, M
Graeff, H
Citation: W. Kuhn et al., Prognostic significance of urokinase (uPA) and its inhibitor PAI-1 for survival in advanced ovarian carcinoma stage FIGO IIIc, BR J CANC, 79(11-12), 1999, pp. 1746-1751
Risultati:
1-24
|